newsfilter
← Latest News
PR Newswire·

Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards

– TERLIVAZ® (terlipressin) is the only FDA approved treatment for adults with HRS with rapid reduction in kidney function1 – DUBLIN, May 5, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty